{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Eikon+Therapeutics", "query": { "sponsor": "Eikon Therapeutics" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T11:30:52.547Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06246110", "title": "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "EIK1001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2024-02-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 38, "location_summary": "Daphne, Alabama • Chandler, Arizona • Fresno, California + 33 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06246110" }, { "nct_id": "NCT06253130", "title": "A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "IMP1734", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 156, "start_date": "2023-12-11", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 23, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06253130" }, { "nct_id": "NCT04819373", "title": "BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "BDB001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-08-30", "completion_date": "2023-05-01", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04819373" }, { "nct_id": "NCT04196530", "title": "BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "BDB001 (EIK1001)", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-11-21", "completion_date": "2024-08-15", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 5, "location_summary": "Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04196530" }, { "nct_id": "NCT06907043", "title": "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "EIK1004-001 (IMP1707-001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 130, "start_date": "2025-04-30", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 6, "location_summary": "Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06907043" }, { "nct_id": "NCT03486301", "title": "BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "BDB001 (EIK1001)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2018-02-15", "completion_date": "2024-04-30", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 5, "location_summary": "Sarasota, Florida • Morristown, New Jersey • Nashville, Tennessee + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03486301" }, { "nct_id": "NCT04840394", "title": "Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "BDB018", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-06-22", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 3, "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • San Antonio, Texas", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840394" }, { "nct_id": "NCT07365319", "title": "A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer (Squamous or Non Squamous)", "Stage 4 NSCLC" ], "interventions": [ { "name": "EIK1001", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Paclitaxel + Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel + Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin /Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2026-06-15", "completion_date": "2040-12-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 16, "location_summary": "Daphne, Alabama • Glendale, California • Orange, California + 13 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07365319" }, { "nct_id": "NCT06697301", "title": "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "EIK1001", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA® )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 740, "start_date": "2025-05-22", "completion_date": "2040-12", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 14, "location_summary": "Chandler, Arizona • Hot Springs, Arkansas • Los Angeles, California + 11 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06697301" }, { "nct_id": "NCT07262619", "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "MSI-H or dMMR Advanced Solid Tumors", "MSI-H/dMMR Gastric Cancer", "MSI-H/dMMR Colorectal Cancer", "MSI-H/dMMR Gastroesophageal-junction Cancer", "Endometrial Cancer", "Mismatch Repair Deficient or MSI-High Solid Tumors" ], "interventions": [ { "name": "EIK1005", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA® )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-01-20", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-08T11:30:52.547Z", "location_count": 10, "location_summary": "Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262619" } ] }